Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections

BACKGROUND: HER2 testing for samples from recurrent or metastatic disease is recommended by the 2013 update of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines and cytological analysis can be applied to several types of metastatic lesions. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Rieko, Okamoto, Nami, Satou, Masakazu, Kojima, Kenta, Tanaka, Shinichi, Yamashita, Natsumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082585/
https://www.ncbi.nlm.nih.gov/pubmed/26746842
http://dx.doi.org/10.1007/s12282-015-0664-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082585/
https://www.ncbi.nlm.nih.gov/pubmed/26746842
http://dx.doi.org/10.1007/s12282-015-0664-1

Ejemplares similares